Back to Articles
Medications

Every GLP-1 Medication in 2026: The Complete Reference

Health Connect Alliance TeamAugust 2, 20269 min read
Assortment of prescription medications on a pharmacy counter

There are now more GLP-1 products than most people can keep straight, and the names overlap confusingly — two brand names for the same molecule, injectable and oral versions of the same drug, and a pipeline that gets written about as though it were on pharmacy shelves. This is the complete reference as of August 2026: what each drug is, what it is approved for, and how you take it.

Semaglutide products

  • Wegovy — semaglutide injection, approved for chronic weight management. Weekly. Standard maintenance dose 2.4 mg.
  • Wegovy HD — semaglutide 7.2 mg injection, approved March 2026. For patients who tolerate 2.4 mg and have plateaued.
  • Wegovy pill — oral semaglutide 25 mg, launched January 5, 2026. Daily, empty stomach, no more than four ounces of water, wait 30 minutes.
  • Ozempic — semaglutide injection approved for type 2 diabetes. Same molecule as Wegovy, different approved indication and dosing range.
  • Rybelsus — oral semaglutide approved for type 2 diabetes, at lower doses than the Wegovy pill.

Tirzepatide products

  • Zepbound — tirzepatide injection approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Weekly, maintenance doses 5 mg to 15 mg.
  • Mounjaro — tirzepatide injection approved for type 2 diabetes. Same molecule as Zepbound.

Tirzepatide is a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 agonist, which is why it produces larger average weight reductions than semaglutide in head-to-head data.

Other approved options

  • Foundayo (orforglipron) — approved April 1, 2026. A once-daily small-molecule GLP-1 pill with no food or water timing restrictions.
  • Saxenda (liraglutide) — daily injection approved for weight management. Older and less effective than the weekly agents, but still available.
  • Victoza (liraglutide) — the diabetes counterpart to Saxenda.

Why one molecule has two brand names

Ozempic and Wegovy are both semaglutide. Mounjaro and Zepbound are both tirzepatide. The difference is the FDA-approved indication: the diabetes brand and the obesity brand are approved for different conditions, at different dosing ranges, and are covered differently by insurance.

This is not a marketing quirk — it determines coverage. A plan that excludes weight-loss drugs may cover Ozempic for a patient with type 2 diabetes while denying Wegovy for the same person if the indication is weight. Which brand you are prescribed is a coverage question as much as a clinical one.

Under review and in the pipeline

CagriSema (semaglutide + cagrilintide) is under FDA review with approval expected later in 2026.

Retatrutide, MariTide, survodutide, mazdutide, ecnoglutide, pemvidutide, and petrelintide all remain investigational and are not FDA-approved. They cannot be legally prescribed or compounded for weight management. If a provider offers you any of them, that is a reason to look elsewhere.

Compounded versions are a separate category

Compounded semaglutide and tirzepatide contain the same molecules but are not FDA-approved products. They are prepared by licensed compounding pharmacies and are not evaluated for bioequivalence to the branded versions. They are substantially cheaper, and that trade-off is the central decision for most cash-paying patients.

Choosing between them

For most people the practical choice narrows to three: tirzepatide if you want maximal weight loss and can inject, semaglutide if you tolerate it better or have coverage for it specifically, and orforglipron if injections are a barrier. Everything else is either a diabetes indication, an older agent, or not yet available.

Read our semaglutide vs tirzepatide comparison for the head-to-head detail.

Compare Listed Programs

Browse the program directory and our reviews, then check the current terms relevant to your comparison.

Sponsored listing
#1
Editor's Choice

CoreAge Rx

9.9
A+

Featured program in our directory

  • Read our program review
  • Compare current offer terms
  • Ask about included services
  • Check the full billed amount
Read the Review
Check Current Terms
Click here for best pricing
Get Started
Program Information
#2

Super Healthy Rx

9.7
A+

100% Online & Confidential - No Insurance Required

  • Compounded Semaglutide & Tirzepatide
  • Board-Certified US Physicians
  • 100% Online Process
  • Free Discreet Shipping
Read the Review
Check Current Terms
Semaglutide $299/month, Tirzepatide $399/month
Get Started
Program Information
#3

Likeness Rx

9.5
A+

Likeness Rx offers online access to compounded semaglutide and tirzepatide. Its public page lists semaglutide from $79/month; tirzepatide from $129/month.

  • Semaglutide from $79/month; tirzepatide from $129/month
  • Online provider review; prescription required
  • GLP-1 and prescription skincare options
Read the Review
Check Current Terms
Semaglutide from $79/month; tirzepatide from $129/month
Get Started
Program Information

Medical Disclaimer: This article is for general education. Discuss personal treatment questions and symptoms with a qualified healthcare professional. The article does not select a treatment or change your prescription.